HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Bullish +55

How HCA Stock’s Quiet Compounding Changes The Growth Story - Trefis

AI-generated analysis

📉 HCA Healthcare shares have lagged the broader market, trading well below their 52-week highs due to a narrative of slowing growth.

🌬️ Recent financial results were negatively impacted by a mild respiratory season and winter storms that reduced patient volumes.

📈 Over the past three years, HCA's revenue grew at a compound annual rate of 7.9% while earnings per share compounded at 13.3%.

💰 The nearly six-percentage-point gap between revenue growth and EPS compounding serves as the centerpiece of the bullish thesis.

📊 Operating margins have steadily expanded from 14.6% two years ago to 15.7% over the last twelve months.

🔄 The company has reduced its outstanding share count by approximately 19.3% over the past three years through consistent buybacks.

📉 Revenue growth moderated to 6.7% in the last year, but the earnings engine remains robust and less dependent on top-line acceleration.

💵 HCA is currently trading at a trailing P/E multiple of 12.7, which is in the lower half of its 10-year historical range of 7.6 to 17.6.

🔍 The market appears to be pricing in risks while potentially overlooking the powerful mechanics of HCA's earnings compounding.

🎯 The primary investment focus is on whether management can keep the gap between earnings and sales growth wide open.

Bullish Signals
  • HCA demonstrates a powerful ability to compound earnings per share at 13.3% annually, significantly outpacing its 7.9% revenue growth rate over the past three years.
  • Operating margins have shown consistent improvement, rising from 14.6% two years ago to 15.7% in the most recent twelve-month period.
  • The company has successfully reduced its share count by 19.3% over the last three years through disciplined buybacks, concentrating value for remaining shareholders.
  • Current valuation metrics show HCA trading at a P/E of 12.7, which is in the lower half of its 10-year range of 7.6 to 17.6, suggesting potential undervaluation.
  • The business model is engineered to generate meaningful value for owners without requiring heroic top-line growth, providing durability against market headwinds.
Risk Factors
  • Shares have lagged the broader market and are trading well off their 52-week highs, reflecting investor caution.
  • Recent revenue growth has moderated to 6.7% in the last year, contributing to a narrative of slowing growth.
  • Patient volumes were dampened by a mild respiratory season and winter storms, impacting recent financial results.
  • The stock's current valuation gives little credit for its quiet compounding mechanics, potentially leaving value on the table.
Full Analysis
HCA Healthcare (HCA) stock has underperformed the broader market with shares trading well below their 52-week highs, driven by a narrative of slowing revenue growth. Recent results were impacted by a mild respiratory season and winter storms that dampened patient volumes, leading to cautious investor sentiment despite the company's underlying operational strengths. The article argues that focusing solely on top-line sales misses a more powerful dynamic: the significant gap between revenue growth and earnings per share (EPS) compounding. Over the past three years, HCA's revenue grew at a compound annual rate of 7.9%, while EPS compounded at 13.3%. This nearly six-percentage-point gap highlights the company's ability to create value without relying on heroic sales expansion. Two primary levers drive this earnings compounding: improving operating margins and consistent share buybacks. Operating margins have steadily expanded from 14.6% two years ago to 15.7% over the last twelve months, while share count has reduced by approximately 19.3% over the same period. These factors allow profits to grow faster than revenue, rewarding shareholders even when top-line growth moderates. Currently trading at a trailing price-to-earnings multiple of 12.7, HCA is valued in the lower half of its 10-year range (7.6 to 17.6), suggesting the market may be overly focused on risks while overlooking the durability of its earnings engine. The key investment thesis rests on management's ability to maintain this gap between earnings and sales growth as revenue potentially re-accelerates.